All In Biotech

Drug Trial Radar · NCT05516914

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

A Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LBL-007 in Combination With Tislelizumab in the Treatment of Malignancies

Last checked: Nov 19, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

98

Actual

Start

Sep 1, 2022

Primary completion

Jan 30, 2026

Study completion Jan 30, 2026

Sponsor

Lead sponsor
Nanjing Leads Biolabs Co.,LtdIndustry
Sponsor type
Industry
First posted
Aug 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is an open and multicenter phase Ib/II clinical study, which aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and effectiveness.

Conditions

  • Malignant Tumors

Interventions

  • LBL-007 InjectionDrug

    Initial dose - MTD; Q3W; intravenous infusion

  • Tislelizumab InjectionDrug

    Initial dose; Q3W; intravenous infusion

  • Cisplatin InjectionDrug

    Initial dose;Q3W; intravenous infusion

  • Gemcitabine Hydrochloride for InjectionDrug

    Initial dose;Q3W; intravenous infusion

  • Docetaxel injectionDrug

    Initial dose;Q3W; intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal (30+7 days after drug withdrawal or before the start of new anti-tumor therapy
  2. Dose-limiting toxicities(DLT)Time frame: DLT is defined as toxicity during the DLT observation period. The duration of DLT observation period is from the first dose to 3 weeks after the first dose
  3. Maximum tolerated dose (MTD)Time frame: At the end of Cycle 1 (each cycle is 21days)

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Cancer Hospital

    Hefei, Anhui, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • Sun Yat-Sen Memorial Hospital,Sun Yat-Sen University

    Guangzhou, Guangdong, China

  • Huizhou Municipal Central Hospital

    Huizhou, Guangdong, China

  • Guangxi Medical University Cancer Hospital

    Nanning, Guangxi, China

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China

  • The First People's Hospital of Yu Lin

    Yulin, Guangxi, China

  • The Second Affiliated Hospital of Hainan Medical University

    Haikou, Hainan, China

  • Zhejiang Cancer Hospital

    Hangzhou, Hangzhou, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • Union Hospital Tongji Medical College Huazhong University of Science And Technology

    Wuhan, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Jiangxi Cancer Hospital

    Nanchang, Jiangxi, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.